AmblyopiaDigital healthChildren's health
What this study is
To evaluate the effectiveness of enhanced binocular amblyopia treatments in achieving a more complete and stable recovery.
What's being tested
- Binocular games for treatment of amblyopia
Intervention · OTHER
playing binocular games on a tablet platform 1 hour per day 5 days per week with reduced contrast for the fellow eye and high contrast for the amblyopic eye
Study details
- Sponsor
- Retina Foundation of the Southwest
- Conditions
- Amblyopia
- Enrolling
- 120 people
- Starts
- 2017-08-31
- Est. completion
- 2025-12-31
- Design
- Open-label, randomized, parallel groups
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 4 Years – 10 YearsSex ALLHealthy volunteers Not acceptedYou may qualify if
- Age 4-10 y
- Male and female
- Strabismic, anisometropic, or combined mechanism amblyopia
- Amblyopic eye best-corrected visual acuity 0.3-0.8 logMAR
- Fellow eye best-corrected visual acuity ≤0.1 logMAR
- Interocular visual acuity difference ≥0.3 logMAR
- Wearing glasses (if needed) for 8 weeks or no change visual acuity with glasses at 2 visits; 4 weeks apart.
- Child's ophthalmologist and family must be willing to forgo patching treatment during the 12-week study period
- Parent's informed consent
- Child must demonstrate understanding and ability to play binocular games
You can't join if
- Prematurity ≥8 weeks
- Coexisting ocular or systemic disease
- Developmental delay
- Strabismus >5pd
- Any binocular amblyopia treatment in the past 3 months
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
1
Study locations (1)
1 openRetina Foundation of the Southwest
Dallas, Texas, United States
- Pediatric Laboratory · Contact2143633911 ext. 113
- Eileen E Birch, PhD · Principal investigator
Recruiting
Study team
Sponsor
Retina Foundation of the Southwest
Study ID 062010-105
Have questions? The contacts above can answer them before you apply.
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.